» Articles » PMID: 22639982

Under-recognized Complications in Patients with Paroxysmal Nocturnal Haemoglobinuria: Raised Pulmonary Pressure and Reduced Right Ventricular Function

Overview
Journal Br J Haematol
Specialty Hematology
Date 2012 May 30
PMID 22639982
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary hypertension is becoming a recognized complication of the hereditary and acquired haemolytic anaemias, associated with a poor prognosis. Recently we reported that patients with paroxysmal nocturnal haemoglobinuria (PNH) have high levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), a biomarker associated with both right and left ventricular dysfunction and cardiac dysfunction. In the current study we evaluated a cohort of patients (N = 29) with haemolytic PNH for elevated pulmonary artery systolic pressure and cardiac function by Doppler-echocardiography. Of the 29 patients, eight were further studied using cardiac magnetic resonance imaging (MRI), as well as two additional patients (number of patients studied using cardiac MRI = 10). Plasma from the first cohort (N = 29) demonstrated intravascular haemolysis associated with a 12-fold increase in median nitric oxide (NO) consumption when compared with healthy volunteers (P < 0·001). Doppler echocardiography demonstrated normal left ventricular function and elevated pulmonary artery systolic pressure in 41% of patients. Cardiac MRI from the second cohort (N = 10) demonstrated depressed right ventricular function in 80% of PNH patients tested, and 60% had findings suggestive of subclinical small pulmonary emboli. Together, these data suggest a high prevalence of haemolysis-associated NO scavenging, Doppler-estimated systolic pulmonary hypertension, and depressed right ventricular function in patients with PNH.

Citing Articles

Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment.

Kokoris S, Polyviou A, Evangelidis P, Grouzi E, Valsami S, Tragiannidis K Int J Mol Sci. 2024; 25(22).

PMID: 39596172 PMC: 11594924. DOI: 10.3390/ijms252212104.


Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement....

Panse J, Daguindau N, Okuyama S, Peffault de Latour R, Schafhausen P, Straetmans N PLoS One. 2024; 19(7):e0306407.

PMID: 39079163 PMC: 11285951. DOI: 10.1371/journal.pone.0306407.


Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab.

Lee H, Park J, Jang H, Lee S, Kim J Eur J Clin Pharmacol. 2024; 80(9):1325-1338.

PMID: 38814441 PMC: 11303580. DOI: 10.1007/s00228-024-03703-8.


Characteristics of paroxysmal nocturnal hemoglobinuria patients in Brazil: A retrospective administrative claims database analysis of PNH patients in Brazilian public healthcare system.

Gualandro S, Salvino M, Alves L, Jeha T PLoS One. 2023; 18(7):e0288708.

PMID: 37494350 PMC: 10370764. DOI: 10.1371/journal.pone.0288708.


Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study.

Chatzileontiadou S, Hatjiharissi E, Angelopoulou M, Asimakopoulos J, Loutsidi N, Chatzikonstantinou T Front Oncol. 2023; 13:1128994.

PMID: 36959785 PMC: 10028290. DOI: 10.3389/fonc.2023.1128994.